The QualityStocks Daily Wednesday, February 3rd, 2021

Today's Top 3 Investment Newsletters

Tip.us(RNWR) +428.85%

QualityStocks(LFLS) +143.90%

MarketBeat(CLNN) +101.99%

The QualityStocks Daily Stock List

Top Strike Resources Corp. (TPPRF)

OTC Markets, InvestorX, Street Insider, Dividend.com, Global Banking and Finance, StocksCafe, PR Newswire, MarketWatch, The Globe and Mail, InvestorIntel, TipRanks, GuruFocus, EIN Presswire, Smarter Analyst, Simply Wall St, BOE Report , CannabisFN, TradingView, Analyst Ratings, Dividend Investor, Midas Letter, Stockwatch, CEO.ca, EOD Data, Morningstar, Newswire.ca, Wallet Investor, Barchart, Nasdaq, News Break, Stockhouse, GlobeNewswire, Mining and Energy, and Seeking Alpha reported earlier on Top Strike Resources Corp. (TPPRF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Top Strike Resources Corp. d.b.a. "Vencanna Ventures" is working to be a go-to capital provider for early-stage global cannabis initiatives with an emphasis on strong management operating in State compliant jurisdictions with barriers to entry. It operates as a merchant capital firm and provides capital for early-stage international cannabis initiatives, including State compliant opportunities in the United States. The Company formerly went by the name Colossal Resources Corp. It changed its name to Top Strike Resources Corp. in December of 2012. OTCQB-listed, Top Strike Resources is based in Calgary, Alberta.

On September 24, 2018, the Corporation announced the completion of a recapitalization financing, the appointment of a new Management team and Board of Directors and start of trading on the CSE. The transactions transitioned the Corporation from an oil and gas issuer to a merchant capital firm, rebranded as "Vencanna Ventures".

Top Strike Resources d.b.a. Vencanna Ventures aims to provide capital, liquidity, and expertise to early stage jurisdictionally compliant cannabis initiatives therefore providing its investors with a high growth cannabis investment strategy. The Company focuses on creating shareholder value through building a diversified portfolio of early stage transformative assets across the U.S. and beyond.

Vencanna Ventures is targeting opportunities with high potential returns (3 to 5x ROI (Return on Investment) within 2 to 5 years). The Company is leveraging its experience to provide exposure to investments in the high growth, developing global cannabis industry. Its strategy is to source at or near cash flow positive opportunities with low upfront capital outlays.

Vencanna Ventures has operating experience throughout the value chain. This includes cultivation, processing, product placement, and distribution experience. Furthermore, its team has greater than 100 years of combined corporate finance, capital markets, and direct investing experience. Vencanna has a large and growing network across North America within industry, regulatory, buy side, and sell side contacts.

Recently, Top Strike Resources Corp. d.b.a. Vencanna Ventures provided a summary of its financial results as of October 31, 2020. As of the date thereof, a significant portion of its business was derived from material ancillary involvement in U.S. cannabis-related activities. As at October 31, 2020, 66 percent of the Corporation's assets and 100 percent of other income was directly related to U.S. cannabis activities.

Top Strike Resources Corp. (TPPRF), closed Wednesday’s trading session at $0.0224, even for the day, on 30,000 volume. The average volume for the last 3 months is 3,465 and the stock's 52-week low/high is $0.009999999/$0.026.

Loans4Less.com, Inc. (LFLS)

Tip.us, FeedBlitz, PennyStocks24, AheadoftheBulls.com, Penny Stock Pulse, 24-7 Stock Alert, Penny Stock Explosion, PremiereStockAlerts, SeriousTraders, Penny Stock Rumble, SmallCapVoice, OTC Picks, MyBestStockAlerts, INO.com Market Report, Greenbackers, Stocknewscast.com, ChartPoppers, Street Beat and Penny Stock Racer reported earlier on Loans4Less.com, Inc. (LFLS), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Loans4Less.com, Inc. is a State of California online Mortgage Broker for conforming residential mortgages. The Company features very competitive rates, terms and costs, daily rate updates, as well as other market information. Headquartered in Torrance, California, Loans4Less.com does not operate a warehouse line of credit, hold trust funds, lend directly or service loans. The Company’s shares trade on the OTC Markets.

Loans4Less.com relies on different wholesale lenders for its retail home loan programs. It looks to engage a strategic partner to broaden the Loans4Less generic Federal Service Mark to maximize its shareholders value. Since 1993, it has successfully helped its clients close on excellent rates.

Loans4Less.com’s aim is to offer the lowest deliverable rates and closing costs. The Company offers premier guidance and service to all borrowers. It does not quote rates and/or points that are not deliverable. Loans4Less cannot provide Borrowers with below market non-deliverable interest rates, points and/or closing costs. The Company does not practice inducement tactics by posting at its website unrealistic quotes.

In addition, Loans4Less.com does not sell or pass on a client’s confidential information to any third party. The Company cannot register their loan or order their credit factual report without an executed Borrower's Certification and Authorization Form and six key items comprising of the Application.

Loans4Less.com owns Union Discount Mortgage, Inc. This is a licensed CA Real Estate Corporation and Mortgage Broker. Union Discount Mortgage controls the rights to certain intellectual property (IP). This includes, but is not limited to, the Loans4Less.com web site and the Loans4Less® Federal Service Mark. The Loans4Less.com and Loans4Less® service mark are used to advertise Union Discount Mortagage, Inc. as a Mortgage Broker and not as a Lender.

Mr. Steven M. Hershman is the President, Treasurer, Chief Financial Officer, and Chairman of the Board of Loans4Less.com, Inc. Mr. Hershman has devoted his efforts to Loans4Less.com as a Mortgage Broker. He holds a California Real Estate Broker License. In 1990, Mr. Hershman became a mortgage broker and he established Union Discount Mortgage, Inc. in April of 1993.

Loans4Less.com, Inc. (LFLS), closed Wednesday’s trading session at $0.09, up 143.9024%, on 44,494 volume. The average volume for the last 3 months is 10,158 and the stock's 52-week low/high is $0.010999999/$0.147699996.

iAnthus Capital Holdings, Inc. (ITHUF)

InvestorPlace, Trading For Keeps, MarketBeat, Wealth Insider Alert, TopPennyStockMovers, MarketClub Analysis, Insider Wealth Advice, CFN Media Group, Cabot Wealth, Penny Stock Rumble, SmallCapVoice, OTC Picks, MyBestStockAlerts, INO.com Market Report, Greenbackers, Stocknewscast.com, ChartPoppers, Street Beat and Penny Stock Racer reported previously on iAnthus Capital Holdings, Inc. (ITHUF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

iAnthus Capital Holdings, Inc. is a provider of capital investment and management services to licensed cannabis cultivators, processors, and dispensaries across the U.S. The Company, by way of its 100 percent owned subsidiary, iAnthus Capital Management, LLC, delivers a complete solution for financing and managing these enterprises. iAnthus supports a diverse portfolio of cannabis industry investments. OTCQX-listed, iAnthus Capital Holdings is headquartered in New York, New York.

iAnthus provides a unique combination of capital and practical operating and management expertise. The Company creates agreements that establish valuable partnerships. It has developed strategic partnerships with best-in-class industry-sector leaders in dispensary operations, commercial-scale cannabis cultivation, regulatory law, and the science of cannabis product formulation and testing. Moreover, iAnthus continues to market its award-winning line of MPX-branded products.

At present, iAnthus has operations in 11 states, and operates 20 dispensaries. The Company is rapidly progressing its long-term plan to install more than half-a-million square feet of cultivation at its Lake Wales, Florida, campus. iAnthus’ New York State operation is one of only ten licensed medical cannabis Registered Organizations in the State. In addition, the Company’s Brooklyn location opened in late 2018. It is one of only three stores serving a city of 2.6 million.

iAnthus Capital Holdings has opened two dispensaries in Florida. This includes its flagship store in West Palm Beach. iAnthus has plans to quickly expand through 2019. It will be adding roughly one store a month. At the same time, it will be expanding its cultivation and processing operations.

In the State of Massachusetts, iAnthus is building a 41,000-square-foot facility. It will accommodate a fully integrated license, which includes cultivation, production and a dispensary on 12 acres in the Fall River area. This is in addition to the Company’s 30,000-square-foot facility in Holliston. Furthermore, in Vermont, iAnthus has made major upgrades to its 6,000-square-foot cultivation and processing facility in Brandon. The Company has also started construction on a 49,700-square-foot medical cannabis cultivation and processing facility in Warwick, New York.

Recently, iAnthus Capital Holdings announced that it opened its second New York dispensary in the Dutchess County town of Wappingers Falls. This dispensary will operate as "Citiva Hudson Valley" under the iAnthus' "Citiva" New York dispensary brand. This retail location will initially offer greater than 30 locally-sourced, lab-tested products, including vape cartridges, tinctures, capsules, and powders, dispensed by highly-knowledgeable patient care representatives.

iAnthus Capital Holdings, Inc. (ITHUF), closed Wednesday’s trading session at $0.2984, up 57.0526%, on 5,104,056 volume. The average volume for the last 3 months is 1,582,153 and the stock's 52-week low/high is $0.046/$1.49.

Blue Line Protection Group, Inc. (BLPG)

Cannabis Financial Network News, Penny Stock Hub, DSR News, Elite Stock Alerts, BestDamnPennyStocks, Journal Transcript, TheNextBigTrade, TheTradingReport, Shiznit Stocks, SmallCapGrowth, InvestorPlace, GrowthPennyStocks, SmallCapVoice, StockRunway, CFN Media Group and Penny Stock General reported beforehand on Blue Line Protection Group, Inc. (BLPG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Blue Line Protection Group, Inc. provides consulting, armed security, compliance and investigations, transportation, and secure vaulting services to banks, businesses and government entities. The Company’s professional team consists chiefly of former military and law enforcement personnel with decades of experience in protection, investigations, logistics, and tactical industries. Blue Line Protection Group is based in Denver, Colorado and lists on the OTC Markets.

The Company works side-by-side with retail establishments. It lessens the risk of criminal activity and creates a secure retail experience through protecting businesses on-site and securing their assets on the road.

Blue Line helps retailers remain compliant with all applicable laws. Furthermore, it shows retail establishments how to protect their businesses through letting Blue Line assume the responsibility and liability for their protective services.

The Company serves banks and credit unions through providing currency processing and transportation solutions. Its risk mitigation services help financial institutions serving cash-intensive industries comply with federal “know your customer” mandates. Blue Line Protection Group announced in October of 2018 that its Cash In Transit (CIT) operations, including vaulting, processing, and tactical compliance, is now available in Arizona.

Blue Line acts on behalf of banks and credit unions through collecting cash sales revenue from their client locations. Upon collecting the currency, the Company transports it to one of its secure processing facilities. Blue Line provides currency handling and validation services for the bank and transportation of processed currency to the Federal Reserve.

Blue Line Protection Group and Hypur have plans to open a cash vaulting and processing facility. This is to serve marijuana-related businesses (MRBs) and cash-intensive businesses (CIBs) in Nevada. Blue Line plans to partner with Hypur to expand services to Arizona, Oregon, Washington, California and Nevada. Hypur is a financial technology company based in Scottsdale, Arizona. The new Nevada facility will implement “Hypur Vault” cash management technologies.

Blue Line Protection Group’s Professional Affiliations include National Cannabis Industry Association, ASIS International, Marijuana Industry Group, Society of Corporate Compliance and Ethics, and Marijuana Business Association. Its Professional Affiliations also include International Association of Chiefs of Police, Professional Private Investigators Assn of Colorado, and Society for Human Resources Management.

Blue Line Protection Group, Inc. (BLPG), closed Wednesday’s trading session at $0.005, up 61.2903%, on 21,432,811 volume. The average volume for the last 3 months is 32,814,585 and the stock's 52-week low/high is $0.000199999/$0.009999999.

Nexeon MedSystems, Inc. (NXNN)

TaglichBrothers and MarketBeat reported earlier on Nexeon MedSystems, Inc. (NXNN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Nexeon MedSystems, Inc. centers on providing innovative neurostimulation products. Its focus is on providing neurostimulation products that improve the quality-of-life of patients suffering from debilitating neurological diseases. Nexeon MedSystems has offices in Dallas, Texas and Liege, Belgium (Nexeon MedSystems Belgium SPRL). The Company’s shares trade on the OTC Markets Group’s OTCQB.

Nexeon MedSystems Belgium, SPRL (NMB) has acquired Medi-Line. This is a Belgian medical device manufacturer. Currently, Medi-Line serves numerous medical device customers in 16 nations. It has multi-year contracts with Fortune 500 companies.

MedSystems is an international bioelectronics medical device company. It has developed and commercialized a neurostimulation system. The system can be used to treat a variety of neurological diseases. Neurostimulation systems are used to restore neuronal function. The Company’s SYNAPSE™ device is the platform used in a process called Deep Brain Stimulation (DBS).

The platform acts like a brain pacemaker sending electrical pulses to specifically targeted areas in the brain. SYNAPSE™ reduces shortcomings in present-day DBS therapy. It enables the detection, measurement, as well as collection of brain signals, while simultaneously providing targeted DBS therapy. Furthermore, it provides directional stimulation that limits side effects.

Additionally, manifold stimulation frequencies permit increased therapy range. As well, rechargeable means a greater range of available therapies and rechargeable enables one surgery in comparison to many.

This past November, Nexeon MedSystems announced that it received grant matching funds from the Puerto Rico Science, Technology, and Research Trust. The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) earlier awarded a $830,000 grant to Nexeon’s wholly-owned subsidiary, Nexeon MedSystems Puerto Rico Operations Corporation (NMPROC, Nexeon PR).

This funding will go to support the development of novel cloud-based software to improve programming for deep brain stimulation. The National Institutes of Health announced funding of over 200 new awards, totaling greater than $220 million, by way of the Brain Research Advancing Innovative Neurotechnologies (BRAIN) Initiative.

Nexeon MedSystems, Inc. (NXNN), closed Wednesday’s trading session at $1.20, up 1,096.41%, on 3,100 volume. The average volume for the last 3 months is 1,600 and the stock's 52-week low/high is $0.000099999/$1.45000004.

Reliq Health Technologies, Inc. (RQHTF)

PHUB News, DSR News, Penny Picks, Equities.com, Damn Good Penny Picks, The Observer, PennyPickAlerts and Fortune Stock Alerts reported  earlier on Reliq Health Technologies, Inc. (RQHTF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Reliq Health Technologies, Inc. is a technology company focused on creating innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare. Its robust iUGO Care platform supports care coordination and community-based healthcare. The iUGO Care platform integrates wearables, sensors, voice technology and intuitive mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators. The Company formerly went by the name Moseda Technologies, Inc. It changed its name to Reliq Health Technologies, Inc. in May 2016. OTCQB-listed, Reliq Health Technologies is based in Hamilton, Ontario.

Reliq’s platform provides automated remote patient monitoring in the home. It supports secure communication between all members of the patient’s circle of care. The Company has developed a novel SaaS (Software-as-a-Service) solution for the Community Healthcare market.

The iUGO Care platform turns the patient’s home into a “virtual hospital ward” utilizing an automated two-way voice, proximity sensors, as well as biometric monitoring devices. Data collected in the home is automatically uploaded to the iUGO Care secure cloud. There, it is available to all members of the patient’s circle of care, with automated alerts if a patient’s condition starts to deteriorate. The iUGO Care platform improves medication adherence.

This past October, Reliq Health Technologies announced that it was chosen by Premier Health Group, Inc. (OTCQB: PHGRF) as its exclusive technology partner. Reliq will provide Premier’s HealthVue primary care clinics with a HealthVue-branded telemedicine, remote monitoring & artificial intelligence (AI) solution for its clinical staff and greater than 100,000 active patients.

HealthVue is a British Columbia-based wholly-owned subsidiary of Premier Health Group. HealthVue focuses on employing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and AI.

Recently, Reliq Health Technologies announced that subsequent to the closing of its Vancouver, British Columbia office, it completed key new hires and engagements to support the Company’s anticipated growth in 2019 and beyond.

Dr. Lisa Crossley, Reliq Health Technologies’ Chief Executive Officer, said, “ “We are thrilled to announce the addition of two new members of the Reliq Health leadership team and the engagement of two new key partners. Dr. Bassma Ghali has accepted the role of CTO with the company, and Mr. Lucas Smithen will take on the position of VP Products & Professional Services… The Company has also engaged Mr. Paul McCulloch to manage Reliq’s cybersecurity, privacy and policy development… Reliq has also engaged Sonique Ltd to support the Company in marketing strategy, digital & social media and creative services…”

Reliq Health Technologies, Inc. (RQHTF), closed Wednesday’s trading session at $0.5839, up 33.6156%, on 7,555,266 volume. The average volume for the last 3 months is 254,550 and the stock's 52-week low/high is $0.080300003/$0.620000004.

ReelTime Rentals, Inc. (RLTR)

PennyStocks24, Real Pennies and Juicy Penny Stocks reported previously on ReelTime Rentals, Inc. (RLTR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

ReelTime Rentals, Inc. (d/b/a ReelTime VR, ReelTime Media Group) is a multimedia publishing business. The Company engages in helping individuals that have been thrust into the public eye to monetize their exposure and control the portrayal of their story. In addition, it develops, produces, and distributes Virtual Reality (VR) Content and technologies under the brand ReelTime VR. ReelTime is headquartered in Seattle, Washington and lists on the OTC Markets.

ReelTime has end to end production, editing, and distribution capabilities for internal and external projects. At present, the Company produces three ongoing series for the Samsung Gear VR platform, VeeR TV, Oculus. It distributes them over manifold VR delivery sites.

Regarding Partnerships, ReelTime partners with other top VR distributors, content producers, and technology providers. Furthermore, concerning its Services, the Company offers Consulting, Production, Monetization, VR Set Design, VR Media Campaigns, as well as VR Content Production.

Pertaining to VR Set Design, ReelTime has a totally-dressed virtual set in its studio facilities. It can create any look one wants for their Virtual Reality show. Also, it can provide traditional virtual set backdrops.

Concerning VR Content Production, ReelTime has a team of editors and other pre/post-production professionals available for all elements of producing VR content. This is from the initial design concepts, to pixel-perfect deliverables.

ReelTime VR announced recently that it became the first to utilize a proprietary technology developed by the Company that allows it to film in full 360 x 360 Virtual Reality formats and simultaneously film in formats compatible with traditional Television platforms. This will allow ReelTime VRs shows the Company produces to not only be available on the rapidly growing premium VR sites it is currently available on, but it will additionally be available for distribution over mainstream Network Television formats and worldwide.

ReelTime has received patent-pending status from the United States Patent and Trademark Office (USPTO) for its non-provisional patent application encompassing apparatus and method claims for technology involving simultaneous capturing of 360 X 360-degree Spherical Panorama Images and Video. The technology will enable any cell phone or other camera to promptly capture 360 X 360 Virtual Reality Video or pictures without any need for stitching.

The VR content is compatible with and can be shared through 360 capable social sites in real time, and on any professional VR platform such as Oculas, Gear VR, Veer VR, Playstation VR, Littlstar, and the HTC Vive.

ReelTime will start using this inventive technology in its production of its award-winning Virtual Reality travel series “In Front of View”. The series commenced filming its second season in Thailand in July. It is shot in English and in Thai. Moreover, ReelTime VR is entertaining licensing agreements with select other VR, film, and TV producers to allow them to also gain a competitive advantage.

ReelTime Rentals, Inc. (RLTR), closed Wednesday’s trading session at $0.37, up 54.1667%, on 1,804,773 volume. The average volume for the last 3 months is 421,586 and the stock's 52-week low/high is $0.008275/$0.39500001.

American Cannabis Company, Inc. (AMMJ)

Promotion Stock Secrets, InvestorPlace, Marketbeat.com, CFN Media Group, Money Morning, Wealth Insider Alert, Stock News Now, The Street, Cannabis Financial Network News, Market Intelligence Center Alert, TheOTCInvestor, Energy & Resources Digest, Daily Trade Alert, Wall Street Daily and MarketBeat reported previously on American Cannabis Company, Inc. (AMMJ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

American Cannabis Company, Inc. is a full-service Business-to-Business  (B2B) consulting solutions provider. It is also a seller of ancillary products to the cannabis industry. The Company provides end-to-end solutions to existing and ambitious participants in the cannabis industry. American Cannabis supports its clients from concept to creation, commercialization and continuing operations. American Cannabis Company has its head office in Denver, Colorado. 

The Company provides complete consulting management and products solutions to the regulated cannabis markets. It uses its industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure, and establish operational best practices. 

American Cannabis has its proprietary product called SoHum Living Soils™. SoHum Living Soils™ is a proprietary "just add water" growing medium. It contains 100 percent natural ingredients. SoHum Living Soils™ provides the plant a complete buffet of macro/micro nutrients to realize genetic optimization of the cannabis plant. 

The Company also owns The Cultivation Cube™, and The High Density Cultivation System™. These are proprietary cultivation products. 

Regarding Consulting, American Cannabis provides application support, business planning, site selection, and regulatory compliance, among other services. Pertaining to Management, the Company provides yield analysis, staffing, business coaching,  and staff training and education, and more. 

Concerning Products, American Cannabis provides a  comprehensive  organic grow system, retail solutions (the Satchel™), and grow components. In addition, it provides group purchasing discounts for supplies. The Satchel is a child-proof, tamper-proof vessel for dispensaries. The Satchel™ may be used by dispensaries to assemble orders and ensure the proper post sale handling of cannabis per each State's legislation.   

American Cannabis has secured a consulting contract with Cloud 9 Apothecary in California. In association with the consulting agreement, it will acquire an equity stake in Cloud 9’s project that is now non-operational and in the development stage. 

The project will comprise a closed-loop greenhouse containing a 22,000 square foot canopy of premium cannabis cultivars. This project will be built-out and completed in Desert Springs, California. 

American Cannabis Company, Inc. (AMMJ), closed Wednesday’s trading session at $0.315, up 74.0331%, on 4,264,746 volume. The average volume for the last 3 months is 1,154,169 and the stock's 52-week low/high is $0.05/$0.319000005.

Natcore Technology, Inc. (NTCXF)

MarketBeat and Vantage Wire reported previously on Natcore Technology, Inc. (NTCXF), and today we choose to report on the Company once again, here at the QualityStocks Daily Newsletter. 

Natcore Technology, Inc. concentrates on using its proprietary Foil Cell technology to considerably lower the costs and improve the power output of solar cells. The Company is creating the next generation of solar cells. Natcore is developing two main technologies. These are low-cost, all-back-contact solar cell structures, and Black Silicon cells.

A solar R&D company, Natcore Technology is headquartered in Rochester, New York. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s Foil Cell (All Back Contact Solar Cell) uses a high-speed, low temperature laser process. Natcore’s Black Silicon technology streamlines the path to low solar cell reflectance.

Natcore Technology has its Natcore Laboratory in Rochester. This is a 19,000 sq. ft. facility. It has 8,000 sq. ft. of ‘class 10,000’ clean room. The Company engages in the full solar cell process at this laboratory - from bare silicon wafer to working cells.

Regarding the Company’s Foil Cell Structure, the process involves multilayer foil metallization. Key features/properties include low cost contact metals and simplified manufacture. This includes low capital equipment cost, small factory footprint, and low temperature processing.

Natcore Technology has established exclusive licenses and/or joint research agreements with Rice University, the National Renewable Energy Laboratory (NREL), Fraunhofer ISE and the University of Virginia. The Company has received 33 patents; 32 patents are pending.

Recently, Natcore Technology announced it significantly streamlined the fabrication method for its pioneering Natcore Foil Cell™. This allows for even lower-cost production methods.

The Company is targeting greater than 25 percent real-world efficiency for its eventual production solar cells. This is approximately a 25 percent performance improvement over numerous high-end commercial cells being installed today.

The use of laser processing to create the Company’s unique, all-back-contact cell structure has been eliminated and replaced by a carrier selective contact process. This is combined with a foil metallization, which can be inexpensively made with high-speed roll-processing methods. Natcore has started an accelerated development program to produce a prototype with the new process, and also include production cost and efficiency modeling by independent authorities.

Natcore Technology, Inc. (NTCXF), closed Wednesday’s trading session at $0.02, up 33.3333%, on 825,355 volume. The average volume for the last 3 months is 124,105 and the stock's 52-week low/high is $0.00075/$0.0225.

OncBioMune Pharmaceuticals, Inc. (OBMP)

Small Cap Firm, QualityStocks, Journal Transcript, Penny Stock Prodigy, Shiznit Stocks, MissionIR, Penny Stock General, KingPennyStocks, Whisper from Wall Street, StockRunway, Otcstockexchange, ProTrader, StockHideout, Value Penny Stocks, OnPoint Stock Alert, GrowthPennyStocks, SmallCapGrowth, Stock Commander, Fortune Stock Alerts, Elite Stock Alerts, BullFreak, MegaPennyStocks, Beacon Equity Research, MicroCapDaily, Wall Street Mover, InvestorSoup, OTCMagic, Penny Stocks Finder, Penny Stock Craze, Penny Stock Finder, 24-7 Stock Alert, Winston Small Cap, PennyPickAlerts, PennyStockLocks.com, SuperStockTips, Seeking Penny Stocks, StockRockandRoll, Stock Preacher and Penny Stock 101 reported earlier on OncBioMune Pharmaceuticals, Inc. (OBMP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OncBioMune Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It engages in the development of targeted cancer therapies, a proprietary cancer vaccine technology, and commercialization of a portfolio of products globally. OncBioMune has a proprietary Vaccine Technology designed to stimulate the immune system to attack its own cancer while not hurting the patient. The Company incorporates scientifically proven and clinically validated treatments for cancer. OncBioMune Pharmaceuticals is based in Baton Rouge, Louisiana. The Company lists on the OTCQB.

OncBioMune Pharmaceuticals’ lead product is ProscaVax™. This is its novel cancer vaccine for prostate cancer. ProscaVax is now undergoing evaluation in a Phase 1 clinical study at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California, funded in part by the Department of Defense US Navy Cancer Vaccine Program.

ProscaVax consists of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Moreover, the Company has a portfolio of targeted therapies. Some of these are biosimilars to blockbuster drugs. OncBioMune has developed the therapeutic cancer vaccine for prostate cancer patients using similar techniques developed for breast cancer patients.

OncBioMune states that it is tested and laboratory proven and that it could become the standard of care for prostate cancer treatment. OncBioMune Pharmaceuticals uses patented technology developed and or acquired by the Company.

In September 2017, OncBioMune Pharmaceuticals announced that it successfully attained development milestones in formulation and stability with tretinoin, also known as all-trans retinoic acid (ATRA). This is an oral drug for the treatment of Acute Promyelocytic Leukemia (APL). The Company owns the commercialization rights for tretinoin throughout Mexico, Central America, and Latin America.

Earlier this month, OncBioMune Pharmaceuticals provided the latest data from its successfully completed Phase 1 trial of ProscaVax for prostate cancer, suggesting a durable response 31 weeks post-therapy. In the Phase 1 clinical trial, hormone-naïve and hormone-independent recurrent prostate cancer patients with rising prostate specific antigen (PSA) were treated with six intradermal injections of ProscaVax.

Dr. Jonathan Head, Chief Executive Officer at OncBioMune Pharmaceuticals, said, “I’m very excited about this data, as I can’t think of another study to have 75 percent of recurrent prostate cancer patients with rising PSA experience stable disease nearly eight months after therapy ended. .. Now, we have to expand the therapeutic range and increase the number of patients enrolled in mid-stage research, but the data to date certainly is encouraging to provide a safe and effective treatments for the millions of men battling prostate cancer today.”

OncBioMune Pharmaceuticals, Inc. (OBMP), closed Wednesday’s trading session at $0.47, up 72.1612%, on 96,272 volume. The average volume for the last 3 months is 5,550 and the stock's 52-week low/high is $0.059999998/$1.25.

Strategic Value Fund Inc. (CLM)

Marketbeat.com, VectorVest, The Online Investor and Daily Markets reported beforehand on Strategic Value Fund Inc. (CLM), and today we highlight the Company again, here at the QualityStocks Daily Newsletter.

Shares of Cornerstone Strategic Value Fund Inc. (NYSE American:CLM) traded at a new 52-week high today of $13.45. This new high was reached on below average trading volume as 253,000 shares traded hands, while the average 30-day volume is approximately 766,000 shares.

Cornerstone Strategic Value Fund Inc. (NYSE American:CLM) has potential upside of 286.4% based on a current price of $13.43 and analysts' consensus price target of $51.89.

In the past 52 weeks, Cornerstone Strategic Value Fund Inc. share prices are bracketed by a low of $5.52 and a high of $13.45 and is now at $13.43, 143% above that low price.

Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, consumer staples, energy, telecommunication services, materials, and other sectors.

Strategic Value Fund Inc. (CLM), closed Wednesday’s trading session at $13.47, up 1.7372%, on 1,223,111 volume. The average volume for the last 3 months is 720,567 and the stock's 52-week low/high is $5.51999998/$13.5249996.

Recruiter.com Group Inc. (RCRT)

Marketbeat.com, VectorVest, The Online Investor and Daily Markets reported beforehand on Recruiter.com Group Inc. (RCRT), and today we highlight the Company again, here at the QualityStocks Daily Newsletter.

Recruiter.com Group Inc. (OTCQB: RCRT), an on-demand video-enabled and artificial intelligence hiring platform with the world’s largest network of recruiters, has acquired Scouted.io. Scouted is a venture capital-backed tech start-up that is committed to developing deep insights into candidates using video screening and AI-based scoring algorithms.

The acquisition was finalized on Jan. 31, 2021, and comprised an asset purchase agreement, with Recruiter.com completing the acquisition primarily with payment of restricted common stock. The announcement notes that Scouted CEO and cofounder Jacqueline Loeb will serve as senior vice president at Recruiter.com. The acquisition supports and strengthens Recruiter.com’s mission of becoming a top-of-mind hiring solution.

“Using video and deep candidate profiling, Scouted understands more about its talent ecosystem than any other system that I have encountered,” said Recruiter.com CEO Evan Sohn in the press release. “We are excited to add Scouted’s exceptional video-based candidate experience to our recruiting process and help small and large employers connect with Scouted’s incredible talent pool of high-potential early- and mid-career professionals.”

To view the full press release, visit https://ibn.fm/IxsvJ

Recruiter.com is a hiring platform for the world's largest network of small and independent recruiters. The company empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology. For more information about the company, please visit www.Recruiter.com.

Clubhouse Media’s management team consists of successful entrepreneurs with financial, legal, marketing, and digital content creation expertise. For more information, follow the company on Twitter: Twitter.com/ClubhouseCMGR?s=20

Recruiter.com Group Inc. (RCRT), closed Wednesday’s trading session at $2.62, off by 3.6765%, on 8,608 volume. The average volume for the last 3 months is 8,548 and the stock's 52-week low/high is $1.00/$3.29999995.

Merus N.V. (NASDAQ: MRUS)

Schaeffer's, InvestorPlace, MarketClub Analysis, The Street, Top Pros' Top Picks, StreetInsider, MarketBeat, StockMarketWatch, BUYINS.NET, Wealth Insider Alert, TradersPro and Daily Trade Alert reported previously on Merus N.V. (MRUS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Merus (NASDAQ: MRUS), focused on the development of innovative, full-length multispecific antibodies, has closed an underwritten public offering of 5,575,757 shares of common stock, including an additional 727,272 shares per the full exercise of the over-allotment option granted to the underwriters.

Merus secured approximately $138 million in gross proceeds, with each of the shares sold at the public offering price of $24.75. The company intends to use the proceeds to advance clinical development of its product candidates, for preclinical research and technology development, as well as for working capital and general corporate purposes. ROTH Capital Partners acted as co-manager for the offering.

To view the full press release, visit https://ibn.fm/soGVC

Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics(R). Multiclonics(R) are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For more information, please visit www.Merus.nl.

Merus N.V. (MRUS), closed Wednesday’s trading session at $26.10, off by 0.07657%, on 157,362 volume. The average volume for the last 3 months is 181,138 and the stock's 52-week low/high is $10.1800003/$31.2712001.

Avid Technology Inc. (AVID)

MarketClub Analysis, StocksEarning, Schaeffer's, The Street, StreetInsider, MarketBeat, Barchart, Marketbeat.com, Zacks, Buttonwood Research, SmarTrend Newsletters, BUYINS.NET, InvestorsUnderground, StockMarketWatch, Daily Trade Alert, Daily Markets, TopStockAnalysts, INO.com Market Report, StreetAuthority Daily, AllPennyStocks, Investors Alley, MarketWatch, Trades Of The Day, The Street Report, Wyatt Investment Research, Louis Navellier, Greenbackers and The Weekly Options Trader reported previously on Avid Technology Inc. (NASDAQ: AVID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avid Technology Inc. (NASDAQ:AVID) traded today at a new 52-week high of $20.13. Approximately 213,000 shares have changed hands today, as compared to an average 30-day volume of 466,000 shares.

Avid Technology Inc develops and sells software and hardware for digital media production and management. Its products are used in production, film studios, cable television stations, recording studios, and other agencies. The company has operations in the U.S.; the Americas; Europe, Middle East, and Africa; and Asia-Pacific. Most of its revenue is split fairly evenly between the U.S. and EMEA. The company's products are organized into suites, including Artist Suite, which includes video editing and digital audio workstations; Media Suite, which provides newsroom management solutions; Studio Suite, which provides tools for on-air programming; and Storage Suite, which provides products for digital storage. It derives most of the revenue from video and audio products and services.

Avid Technology Inc. (NASDAQ:AVID) is currently priced 66.2% above its average consensus analyst price target of $6.72.

In the past 52 weeks, Avid Technology Inc. share prices are bracketed by a low of $4.67 and a high of $20.13 and is now at $19.90, 326% above that low price.

Avid Technology Inc. (AVID), closed Wednesday’s trading session at $20.94, up 10.0946%, on 2,131,889 volume. The average volume for the last 3 months is 461,485 and the stock's 52-week low/high is $4.67000007/$21.0799999.

The QualityStocks Company Corner

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF)

The QualityStocks Daily Newsletter would like to spotlight TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF).

TAAT(TM) Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) (FRA: 2TP2) has announced that an article profiling the company was published earlier today by Forbes, marking the first national mainstream media coverage of TAAT(TM) in the United States. In the piece, Forbes contributor Amanda Siebert, who primarily covers media stories in the “Vices” category, summarizes her interview with TAAT(TM) CEO Setti Coscarella, in which Coscarella shares his professional background and journey to his current role. To view the full press release, visit https://ibn.fm/nZbOS. Also today, the company was highlighted in a publication from InvestorWire, examining how TOBAF has announced that its flagship product will be represented by CROSSMARK Inc. CROSSMARK is a Texas-based sales and marketing agency with more than 25,000 employees and proven success in commercializing tobacco alternatives. To view the full press release, visit http://ibn.fm/VVpJ2

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) is a life sciences company dedicated to giving legal-aged smokers the choice to keep the smoking experience that they enjoy with no nicotine and no tobacco.

The key players of TAAT Lifestyle & Wellness are from leading tobacco brands. They are guiding the mission with the company’s proprietary product, TAAT(TM), which uses the company’s proprietary Beyond Tobacco(TM) base material. The base material undergoes a 14-step process to taste and smell just like tobacco and uses a patent-pending refinement technique.

This provides the company with unique opportunities on the global tobacco market, which was estimated at $849 billion in 2019, with approximately 1.3 billion people using tobacco in some form worldwide (https://nnw.fm/bvKFL).

TAAT Lifestyle & Wellness was founded in 2006 and is headquartered in Vancouver, Canada, with operations in Las Vegas, Nevada.

TAAT(TM)

TAAT is a smokable alternative to tobacco cigarettes using the Beyond Tobacco base material, which contains zero tobacco and zero nicotine. The current TAAT offering comes in three varieties: Original, Smooth and Menthol, which were launched during Q4 2020 in Ohio. The company’s Ohio tobacco wholesaler also distributes for major tobacco industry names such as Altria, RJ Reynolds (a subsidiary of British American Tobacco) and ITG.

The TAAT Beyond Tobacco experience was created to replicate the sensory elements of smoking a tobacco cigarette. Market testing in California and Nevada reached a consensus that TAAT products offered no significant differences in experience when compared to tobacco cigarettes, in terms of the following aspects:

  • Visual – the nearly identical product packaging and enhanced smoke volume
  • Auditory – the “crackling” sound of the base material when it is ignited
  • Smell – when burning, TAAT emits a tobacco-like scent
  • Taste – the patent-pending Beyond Tobacco base material undergoes a refinement process that creates a tobacco-like taste
  • Touch – TAAT satisfies the “hand-to-mouth” fixation and motor habits, such as flicking ashes

TAAT Beyond Tobacco Targeting Current Smokers

TAAT Lifestyle & Wellness is currently targeting the market of legal-aged smokers with its proprietary product. The company aims “not to create a new problem, but to solve an existing one.” TAAT Lifestyle & Wellness offers a non-addictive alternative to tobacco, with several competitive advantages making it a promising option on the United States market, such as:

  • Price – TAAT can be offered at a lower price than competing products in the tobacco category, which adds to the propositioned value for current legal-aged smokers.
  • Experience – TAAT appeals to current smokers who wish to give up the tobacco and nicotine but keep the smoking experience they enjoy.
  • Branding/Packaging – TAAT is American-grown and American-made, with its Beyond Tobacco base material serving as a legacy to the combustible tobacco products.

The current alternatives to cigarette smoking do not offer a comparable experience. Previously marketed products, like vaping, proved difficult for some legal-aged smokers to adopt, as the experience was too different from traditional cigarettes.

Market Outlook

In 2016, the United States tobacco market was valued at over $100 billion, a number that’s expected to grow over the next decade (https://nnw.fm/yd8oP). In terms of volume, over 215 billion cigarettes were sold to roughly 34 million adults in the United States in 2018. These numbers represent almost 14% of the adult population. Of those, almost two-thirds smoked more than 15 cigarettes in one day. A standard pack is comprised of 20 cigarettes.

The company’s Beyond Tobacco, as a non-tobacco product, has a price-driven consumer advantage in many states. While state taxes on traditional cigarettes vary, most tend to average around $1.82 per pack. Washington D.C. is on the higher end of the tax spectrum at $4.50 per pack, whereas Missouri is only $0.17 per pack (https://nnw.fm/D3WnT).

TAAT Lifestyle & Wellness estimates that, if one pack of TAAT Beyond Tobacco was sold at 20% of all United States tobacco points of sale, the product would capture 0.25% of the market, the equivalent of approximately 2.7 million cartons of cigarettes per year.

Management Team

Setti Coscarella is the Chief Executive Officer of TAAT Lifestyle & Wellness Ltd. He is experienced in investment banking, private equity and entrepreneurship. In 2017, Mr. Coscarella was the lead strategist for Reduced-Risk Products at Philip Morris International. While there, he worked with thousands of smokers to better understand how to position smoking alternatives, developing programs that could help smokers convert to reduced-risk products. Mr. Coscarella holds an MBA from the Schulich School of Business, specializing in finance, marketing and corporate strategy. He also has a Bachelor of Science in mathematics and physics from the University of Toronto.

Tim Corkum is the company’s Chief Revenue Officer. He has a lengthy history in the tobacco industry, having served 21 years at Philip Morris International. Mr. Corkum has experience leading the international commercialization of combustible cigarettes and working on reduced-risk product offerings. During his 21-year tenure, he held senior positions in business development, sales strategy, key account management and corporate affairs. He holds a BA from Carleton University with a concentration in law.

Joe Deighan is Founder of TAAT Lifestyle & Wellness and oversees research and development. He is the founder of vape liquid ‘JJuice’, created in 2012. JJuice was distributed across all of the United States and in 26 other countries, alongside the private label production that was done for other brands. Mr. Deighan sold JJuice in a cash deal that was valued at over $800,000 in 2017. He currently handles all R&D and production for Beyond Tobacco, knowing the product better than anyone else in the company.

TAAT Lifestyle & Wellness Ltd. (TOBAF), closed Wednesday’s trading session at $2.68, up 6.7729%, on 216,571 volume. The average volume for the last 3 months is 173,816 and the stock's 52-week low/high is $0.100000001/$3.31999993.

Recent News

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF)

The QualityStocks Daily Newsletter would like to spotlight HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF).

HempFusion Wellness (TSX: CBD.U), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, announced that it has secured its OTC Markets trading symbol, “CBDHF,” allowing a broader U.S. investor audience the ability to trade shares in the company. “As a U.S.-based CBD company, this important step allows a broader range of U.S. investors to access the company,” said Jason Mitchell N.D., HempFusion’s co-founder and CEO. “Additionally, we have applied for an OTCQX listing and DTC eligibility, which we expect in the coming weeks subject to the approval of the OTCQX and the satisfaction of certain listing requirements.” To view the full press release, visit: https://www.cnw.fm/SPXkS

HempFusion Wellness Inc. (TSX: CBD.U) (FWB: 8OO) (OTC: CBDHF) is a leader in the health and wellness CBD industry, providing innovative and diversified proprietary formulations utilizing the power of whole-food hemp nutrition.

Invested heavily in regulatory compliance, HempFusion aims to consistently meet and even exceed the high standards required by retailers and consumers – putting safety, quality and consistency first. In support of these efforts, the company is U.S. Hemp Authority Certified and is a current board member of the U.S. Hemp Roundtable, a coalition of leading companies committed to advancing safe hemp and CBD products.

HempFusion reported 1,750 shareholders and $18.3 million in cash as of June 30, 2020 – the second-largest cash position in its sector – with no debt. Looking ahead, the company is currently preparing to launch an IPO directly onto the Toronto Stock Exchange (“TSX”) senior board, where it has already reserved ticker symbol ‘CBD.U’. Learn More About HempFusion Upcoming IPO.

HempFusion is headquartered in Denver, Colorado.

HempFusion’s Proprietary Wellness Portfolio

The diverse product portfolio showcased by HempFusion includes 46 products that are currently on shelves. The company’s leading offerings include HempFusion-owned Biome Labs, HF Labs and Probulin. Due to the time and resources allocated to increasing the compliance of these proprietary products, HempFusion may have a competitive advantage and create additional retail opportunities that are not available for other CBD companies.

HempFusion’s Diversified Revenue Pipeline

HempFusion’s focus and investment into regulatory compliance has opened doors to major food and drug mass or big box retailers that are not available to other CBD companies. This strategic approach includes five distinct channels:

  • Natural Health Retailers
  • eCommerce
  • Big Box / Food and Drug Mass
  • Doctor Practitioner
  • Convenience

HempFusion’s Line of Products

HempFusion’s branded line of products is based on the company’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex. Each product is condition-specific, targeting needs such as sleep, energy and stress.

All of HempFusion’s products are made from DNA-verified, European Union registered, non-GMO, organic industrial hemp. The company’s offerings span multiple product categories, including:

  • Tinctures and capsules – These offerings make up the most popular product category in the $4 billion U.S. CBD market.
  • OTC topicals – HempFusion is one of the few CBD companies marketing FDA Drug Listed Topicals. The FDA compliance standards ensure that these products meet the standards set by larger national retailers.
  • Condition-specific OTC products – HempFusion has OTC products that are condition-specifically targeted, including:
    • OTC Pain Products – The global pain relief market for topicals is projected to reach $13.3 billion by 2025, with a CAGR from 2018 to 2025 of 7.4%.
    • OTC Eczema Products – The global dermatitis market is projected to reach $13.6 billion by 2026.
    • OTC Acne and Aging/Beauty Products – The global market for beauty and anti-aging products is currently estimated at $1.08 trillion.
    • OTC First Aid and Wound Healing Products – In 2019, the 10 top-selling first aid ointments in the United States generated over $650 million in sales.

Probulin Probiotics and Digestive Enzymes

Probulin Probiotics is a 100% wholly owned subsidiary of HempFusion Wellness Inc. and is currently one of the fastest growing probiotics brands in the United States, according to Spins syndicated data.

The Probulin product line addresses a wide range of consumer needs, including daily care, total care, women’s health and children’s products. The probiotics market represents a growing opportunity, as it is estimated to reach $7 billion globally by 2022.

Because of the diverse offerings of the Probulin line, it serves as HempFusion’s gateway to retailers who may not currently carry CBD products.

This ‘Trojan Horse Strategy’ is intended to allow the company to establish, develop and build relationships among these retailers. By achieving approved vendor status, the company may be able to facilitate faster onboarding times, enabling accelerated access to its CBD products in the future.

HF Labs and Biome Research – Doctor and Practitioner Product Lines

The HF Labs and Biome Research product lines are directed toward doctors and practitioners and cater to hospitals, compounding pharmacies and free-standing dispensaries. With an estimated target market of 28,000+ integrative medical doctors and 70,000+ licensed chiropractors in the United States, these offerings create a unique market opportunity as HempFusion continues to broaden its footprint in the CBD industry.

Research on CBD and Human Safety

HempFusion is one of 12 CBD companies selected to participate in ValidCare’s groundbreaking study regarding CBD and human safety, which is expected to be complete by the end of October 2020. The study is designed to address previous questions from the FDA regarding CBD products.

As part of this study, HempFusion and the other selected companies will be conducting human trials to determine if the daily use of full-spectrum hemp-derived CBD or CBD isolate impacts the human liver.

Management Team

Jason Mitchell, N.D., is the co-founder, Director and CEO of HempFusion. He has over 20 years of experience in the natural products industry and is a naturopathic doctor certified by the ANMCB. Mitchell received his doctorate from the Trinity College of Natural Health and is a member of the American Naturopathic Medical Association and the CNHP. He is an expert in supplemental formations and was responsible for successfully creating and launching over 300 industry-leading products during his 15-year tenure at Country Life Vitamins.

Ian DeQueiroz is the Chief of Brand Strategy & Partnerships and a Director for HempFusion. He is a serial entrepreneur with experience in early-stage cannabis and hemp companies. In 2010, he acquired his first cannabis CO2 extraction company in the United States. DeQueiroz has facilitated the licensing process for many companies in the United States, as well as one of Jamaica’s premier cannabis companies, Epican Medicinals Ltd.

Jon Visser is HempFusion’s Chief Revenue Officer. He has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multi-national manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Bruce Valentine Jr. is the Chief Financial Officer of HempFusion. He has a proven track record working with high-growth companies and was named CFO of the Year in 2013 by the Northern Colorado Business Report. Valentine is the former CFO of Otter Products and has over 15 years of financial management experience.

Ola Lessard is the Chief Marketing Officer of HempFusion and is also the President of the U.S. Hemp Roundtable. She has experience in marketing creative and effective brand strategies. She is a former Vice President of Marketing at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini is the Director of the Doctor/Practitioner Channel. She has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody is the Chief Corporate Officer of HempFusion. He is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF). Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF). Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.

HempFusion Wellness Inc. (CBDHF), closed Wednesday’s trading session at $2.1485, up 17.5007%, on 491,823 volume. The stock's 52-week low/high is $1.65999996/$2.29999995.

Recent News

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

The QualityStocks Daily Newsletter would like to spotlight XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has signed an agreement with Applied Pharmaceutical Innovation. A not-for-profit institution at the University of Alberta, Applied supports translational drug development for industry and innovators. XPhyto’s psychedelic pharmaceutical production agreement calls for the synthesis of pharmaceutical-grade psychedelic compounds and the development of the standard operating procedures required to obtain regulatory approval for the commercial production process. To view the full press release, visit https://ibn.fm/jzCbx

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

  • Commercialization of infectious disease diagnostics
  • Clinical validation of transdermal and sublingual drug formulations
  • Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (CE-IVD) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

  • Rotigotine transdermal patch for Parkinson’s disease
  • CBD oral/sublingual strip for treatment resistant epilepsy
  • THC oral/sublingual strip for anorexia/nausea
  • CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

  • An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
  • An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

XPhyto Therapeutics Corp. (OTCQB: XPHYF), closed Wednesday’s trading session at $2.1879, up 2.699%, on 55,673 volume. The average volume for the last 3 months is 24,729 and the stock's 52-week low/high is $1.3125/$3.0999999.

Recent News

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands (OTCQB: KAVL), a company focused on generating stockholder value by incubating innovative products into mature and dominant brands, is the exclusive global distributor of all products manufactured by Bidi Vapor LLC. This includes Bidi Vapor's primary offering, the Bidi(R) Stick, as well as the Bidi(R) Pouch, a tobacco-free nicotine pouch. Today Kaival Brands announced its entry into an agreement with H.T. Hackney Co., a longstanding convenience store distribution leader, under which Hackney can now purchase the Bidi(R) Sticks for distribution. To view the full press release, visit https://ibn.fm/f9Ntd

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Wednesday’s trading session at $1.36, up 10.5691%, on 677,826 volume. The average volume for the last 3 months is 634,372 and the stock's 52-week low/high is $0.008/$1.41999995.

Recent News

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) was featured today in a publication from BioMedWire, examining how, for over 30 years, the standard of visualizing bladder cancer during surgery has been white light illumination through an endoscopic procedure called a cystoscopy. When performing a cystoscopy, the surgeon uses the scope and white light to identify and remove the tumors that protrude above the bladder. Therein lies the problem, as the finer edges that need to be resected are not always clearly defined and tumors that lay flat against the bladder wall are often not visible using this technology. This inability to resect completely may contribute to the over 50% recurrence rate of bladder cancer.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Wednesday’s trading session at $0.7439, up 5.3533%, on 66,330 volume. The average volume for the last 3 months is 46,000 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a cannabis and hemp-branded products company in the United States, has announced an upcoming shareholder meeting. The meeting, scheduled for 10 a.m. ET on Feb. 25, 2021, is an extraordinary meeting of holders of 8% unsecured convertible debentures that are due Feb. 28, 2021. Information containing detailed information regarding the amendments and resolutions to be considered during the meeting has been mailed to the company’s debentureholders of record. To view the full press release, visit: https://www.cnw.fm/EHkrP

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Wednesday’s trading session at $0.67311, up 5.1406%, on 141,736 volume. The average volume for the last 3 months is 102,344 and the stock's 52-week low/high is $0.279000014/$1.02999997.

Recent News

HYB Holding Corp. (OTC: HYBG)

The QualityStocks Daily Newsletter would like to spotlight HYB Holding Corp. (OTC: HYBG).

HYB Holding (OTC: HYBG), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format. A recent article discussing the company reads, “The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems.” To view the full article, visit https://ibn.fm/VbEHi

HYB Holding Corp. (OTC: HYBG), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format.

The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems.

HYB Holding Corp. acquired all of Mediscan’s capital stock in a reverse acquisition transaction on November 13, 2020. On November 23, 2020, the shareholders of HYB Holding Corp. consented to a resolution changing its name to Healthtech Solutions Inc.

The company’s operational focus for the immediate future will be on Mediscan’s continuing research and development of imaging, development of other medical solutions, and making strategic investments.

Mediscan Technology

Mediscan software transforms an ultrasound analog 2D grayscale image into a digital 3D HD format. When paired with a portable ultrasound machine, the software application can enable these detailed and quantifiable scans by on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (EMS) personnel, and technicians in isolation wards and emergency rooms.

Once an image has been captured in 2D, it is converted using a cloud-based software application process – a process that takes approximately one minute. The completed 3D image is viewed on the medical professional’s computer monitor, pad or smartphone at the point of service. This technique can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves.

This cloud-based software application for ultrasound devices is easy to use anywhere there is an internet connection. The application provides the convenience of point of care ultrasound with the image quality of CT or X-ray and the safety of very expensive MRI technology. For patients, it provides a convenient and comfortable medical experience.

Mediscan has filed two patent applications with the United States Patent and Trademark Office, both for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

The technology will initially be available as medical software-as-a-service (SaaS), resulting in cost-efficiency. The SaaS model eliminates the customer’s need for external hardware and software solutions, as well as technical maintenance. The SaaS model is already widely used in the health care industry, most notably for clinical information systems and supply chain management, revenue cycle management and billing. Benefits include increased patient and physician satisfaction, lower operational costs, better workflows and more. Per company data, the Mediscan system is fast and efficient, which could generate a significant cost reduction.

Health and Wellness Applications

Mediscan’s technology has shown success in musculoskeletal (MSK), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung and or the MSK sub-system, the application directly images the target area, saves it as a reference, and then compares it to previous images, helping to determine if the patient is progressing or regressing.

The cardiac application combines imaging with a therapy system that detects and classifies cardiac myopathy conditions via an “entrainment” process similar to that used in treating tachycardia. This application also features a comparison function where the latest imagery is interpreted against previous vetted cardiac images to detect progression or regression.

Mediscan’s technology can also be utilized on the wellness market for diagnostics and support in a wide range of situations, such as sports injuries, physical therapy and dermatological indications.

COVID-19 Applications

COVID-19 causes complications with patients’ cardiovascular and pulmonary systems. Mediscan’s technology could help meet the growing need for advanced diagnostic and monitoring imaging at the point of care.

Portable ultrasounds equipped with Mediscan’s application are a flexible and easy-to-use solution for health care providers to evaluate, triage and diagnose COVID-19 effects on contagious patients in isolation where MRI, CT or PET Scans are not accessible. With this technology, health care providers can easily detect lung lesions or heart muscle shredding, which often appear in patients with COVID-19.

Diagnostic Imaging Market Outlook

With the increasing demand for early diagnosis and a widening scope of clinical applications, any promising technological advancements in the field constitute a significant investment opportunity. The global market is also being driven by technological advances in the diagnostic imaging industry.

As standard ultrasound 2D greyscale images are generally the norm, and 3D imaging typically requires the use of CT, PET, MRI or X-ray technology, Mediscan’s application could have a dramatic impact on the medical imaging industry, meeting the need for imaging equipment and devices that can generate human anatomy data in 3D.

The global market for diagnostic imaging was estimated at approximately $100 billion in 2016 (https://ibn.fm/xtInK) and was expected to grow steadily, creating a promising opportunity for Mediscan to distribute its technology and achieve its mission as a developer and distributor of medical imaging solutions designed for both long-term care and acute and emergency medical services.

Management Team

David Rubin is the Chairman and CEO of HYB Holding Corp. Mr. Rubin has been in the financial services business for over 20 years. Concurrently, he is also the CEO of Capital Stack LLC and CEO of eProdigy Financial LLC. Rubin attended Kingsborough Community College from 1985 to 1988.

Manuel Iglesias is the President and a Director of HYB Holding Corp. Mr. Iglesias has practiced law since 1980, specializing in business law, merger and acquisitions, securities and health care. Mr. Iglesias served as President, CEO and a board member of Hygea Holdings Corp., which provided primary care medical services throughout Florida and Georgia. He served as the National Chairman of the Republican National Lawyers Association in 2019 and 2020. Mr. Igleisias was awarded his MBA degree from the University of Chicago in 1981, a Juris Doctorate from the University of Chicago in 1979, and a BS in Foreign Service from Georgetown University in 1976.

Denis Kleinfeld is a Director of HYB Holdings Corp. and General Counsel and a Director of Mediscan Inc. Mr. Kleinfeld has extensive experience in business planning and regulatory compliance. Mr. Kleinfeld is a renowned expert in international tax and estate planning law. Kleinfeld received his Juris Doctorate from the Loyola University of Chicago School of Law in 1970.

Richard F. Parker is the Chief Research Officer of Mediscan Inc. He developed the technology that is the foundation of Mediscan’s business plan. Before he joined Mediscan, Mr. Parker was employed as an engineer and business executive for 37 years. Previously, he was President and Chief Technology Officer of CytoWave LLC. Mr. Parker was awarded a patent for technology that supported a Method and Apparatus for Generating a Therapeutic Magnetic Waveform. During the past 10 years, Mr. Parker has published 14 papers and made numerous presentations focused on magnetic imaging and treatment of sports and equine injuries. He obtained his MSEE degree from the Georgia Institute of Technology in 1971.

HYB Holding Corp. (OTC: HYBG), closed Wednesday’s trading session at $0.14, up 6.626%, on 46,978 volume. The average volume for the last 3 months is 34,222 and the stock's 52-week low/high is $0.019999999/$0.189999997.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (NASDAQ). The letter informed Predictive Oncology that the company had regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the exchange’s listing rules. In October 2020, POAI had been notified by NASDAQ that it no longer met the organization’s minimum price bid requirement because it’s closing bid price per share had been below $1 for a period of 30 consecutive business days. To view the full press release, visit http://ibn.fm/qVWOF

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Wednesday’s trading session at $1.23, even for the day, on 1,662,675 volume. The average volume for the last 3 months is 2,260,580 and the stock's 52-week low/high is $0.629999995/$5.30000019.

Recent News

Knightscope, Inc.

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc..

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”), has announced that that it now has 19,000 investors. The announcement, in which Knightscope expressed its gratitude to its investors for their support, comes a few short weeks after the company reported to have closed over 18,000 investors since its inception. The update reads, “To look back to early 2013 when we couldn’t get a single person to believe in us, we are beyond humbled on how far we have been able to get and how much we’ve achieved – because of your kind and gracious support!  Onward!” To view the full update, visit https://ibn.fm/22zjD

Knightscope, Inc., founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities and are on target to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics and artificial intelligence.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including ten Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country, despite the pandemic (note: robots are immune).

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire.

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology;
  • Operating for more than one million hours in the field and securing contracts across five time zones;
  • Navigating through the global pandemic without interruption by continuing to operate on a daily basis across the nation and supporting clients classified as essential services; and
  • Continuing its hiring processes despite the current societal and economic disruption.

Growth Capital

With more than 10,000 investors and over $40 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

The company is presently in the process of raising up to $50 million in growth capital as it prepares for a potential public listing. Knightscope has reserved ticker symbol ‘KSCP’ with Nasdaq.

Investors can buy shares exclusively through the company’s managing broker-dealer, StartEngine (http://nnw.fm/l9GLX) until July 20, 2020. Concurrent with this live offering and contingent upon various factors, including raising a sufficient amount of funds and meeting applicable listing standards, the company intends to begin preparation of an S-1 format Form 1-A and Nasdaq Capital Market application in anticipation of a possible public listing of the stock at the conclusion of the Regulation A+ offering.

Company Mission — The Greater Good

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Crime has a negative economic impact in excess of $1 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was recently interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one to one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings — and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $4 to $11 per hour, compared with approximately $85 and $30 per hour for an armed off duty law enforcement officer and an unarmed security guard, respectively.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has four patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’.

The ASRs and all the related technologies were developed ground up by the Company and are Made in the USA.

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.


Recent News

chart

RYAH Group Inc.

The QualityStocks Daily Newsletter would like to spotlight RYAH Group Inc..

RYAH Group, a leading digital health care analytics and technology company, has entered into a research-and-distribution arrangement THC Lab, which specializes in providing products and services to compounding pharmacies in Italy and other European countries in the specific field of medical cannabis (https://ibn.fm/UPk8j). The agreement outlines the parameters for the launch of RYAH’s IoT dose-measuring Smart-Inhaler and data analytics platform in Italy and the Netherlands.

RYAH Group is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

RYAH Group Inc. is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.

Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.

Product Portfolio

The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.

RYAH Smart-Inhaler

The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.

RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.

In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.

RYAH Smart-Patch

The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.

RYAH Smart-Pen

The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.

RYAH MD

RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.

PotBot App

The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.

Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.

Market Outlook

RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.

In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ).

Management Team

Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.

Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.

Investment Considerations

  • RYAH Group is a technological leader in the plant-based treatment market with its unique combination of proprietary IoT devices and data analytics, supported by patented AI technology.
  • The company’s products pair a growing ecosystem of therapeutic plants with top-rated apps, devices and services.
  • RYAH offers a complete remote dosage delivery and dose-monitoring platform based on data-driven analytics supported by prescribing doctors and their patients.
  • The company is finalizing its anticipated listing on the Canadian Securities Exchange.
  • RYAH holds a unique position on the $100.3 billion medical plant market, with the potential to capture footholds in both the IoT and Data Intelligence industries.

Recent News

chart

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF)

The QualityStocks Daily Newsletter would like to spotlight PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF).

PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) was featured in a recent Forbes article titled, “Sustainably-Focused, Plant-Based Online Groceries Are Thriving. Here’s Why.” The piece covers plant-based groceries and the fact that sustainability focused products are growing at a rate of 5.6 times that of other products in the consumer goods sector. The article reads, “Another driving force for healthy online shopping is the growing impact of the plant-based community. PlantX was born from a combination of the need for education in plant-based living and eating, and co-founder Sean Dollinger’s 20 plus years background in e-commerce. The concept, a one-stop-shop with more than 10,000 plant-based products that ship all over Canada and the USA, was created by merging the two to make a plant-based lifestyle more accessible to all.” To view the full article and press release, visit https://ibn.fm/hNSON and https://ibn.fm/4b9Cc

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based community through e-commerce, with a core objective of becoming the most trusted and convenient destination for people living plant-based lives. PlantX is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, connecting consumers with interactive PlantX brick-and-mortar stores, and a PlantX home delivery system for products, meals, recipes and more.

PlantX is a high-growth technology company focusing on consumer-packaged goods (“CPG”) for the plant-based opportunity. The PlantX platform aims to serve as the digital face of this community with its one-stop-shop for everything plant-based, including:

  • An easy-to-use e-commerce shopping experience featuring the following:
    • Plant-based grocery items (from all your pantry needs to vitamins, cosmetics and even pet food)
    • Meal delivery with recipes created by well-known plant-based chefs throughout the world
    • Plant shop – delivering a wide variety of affordable indoor houseplants to homes across Canada and the U.S.
    • Easy to follow plant-based recipes every week
    • Partnerships with restaurants, nutritionists, chefs and brands
    • A community of like-minded individuals
  • State-of-the-art flagship PlantX locations

Since first launching in February 2020, PlantX Life has offered various services available through its comprehensive platform. This online marketplace features over 10,000 items across diverse product categories such as pantry items, beverages, personal care, pet food and indoor plants. In addition, PlantX has collaborated with renowned chefs and nutritionists to create 20 unique and pre-made meals delivered to the comfort of your own home.

Headquartered in Vancouver, Canada, PlantX’s mission is to spearhead the plant-based movement, celebrate and promote health and wellbeing, raise plant-based awareness in a hyper-palatable world, connect with global consumers and forge a welcoming plant-based community.

The company currently reports 4 million stock options and 24 million warrants outstanding, with a total of 88,832,159 shares issued and outstanding and a total market cap of $89.9 million on January 18, 2021. PlantX has continued to catalyze its capital markets dynamics by applying to list its common shares on the Nasdaq Capital Market (“NASDAQ”). The company’s common shares are eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States.

Market Outlook

With its comprehensive e-commerce platform, PlantX is strongly positioned for a prominent role in the fast-growing plant-based food market, e-commerce and the online food delivery sectors. The global plant-based food market is expected to reach $74.2 billion by 2027, expanding at a CAGR of 11.9%. Similarly, the online food delivery market has steadily grown, especially during the current pandemic. This trend seems here to stay. In the United States alone, the sector is expected to report $28.5 billion by 2024, with companies such as UberEats experiencing 152% increases in food deliveries in the summer of 2020.

Complementary to these trends, and as a result of the COVID-19 pandemic, online sales and digitization have also both grown exponentially in 2020. Grocery shopping has seen a remarkable transition to e-commerce, with online grocery sales growing by 53% in 2020. Amid the pandemic-imposed physical interactions and related consumer behavior change, large retailers have been compelled to meet this surge in e-commerce demand. For example, Whole Foods Markets has increased its online sales capacity by over 60% in 2020. The global meal kit delivery system is also becoming increasingly popular and is expected to achieve a market value of $19.92 billion by 2027, expanding at a CAGR of 12.8%.

PlantX aims to capitalize on this anticipated exponential market growth of the plant-based, e-commerce and home-delivery industries.

Digital Platform for the Plant-Based Community

The digital interface provided by PlantX spans a health and wellness initiative that offers thousands of plant-based products, meal delivery, indoor plants, recipes and a community space for those who are like-minded about plant-based products and healthy lifestyles. PlantX has been compared to Amazon, except with a focused tailored selection of plant-based offerings.

PlantX provides everything a consumer needs for plant-based living at the click of a button. With PlantX, customers can:

  • Shop
  • Find recipes
  • Read blogs
  • Join a community forum
  • Listen to podcasts
  • View cosmetics
  • Research vitamins
  • Purchase plant-based pet foods
  • Read corporate updates
  • Subscribe to an insightful newsletter

The company’s website was designed with a user-friendly interface that allows customers to visit the site and easily find what they need. Forums for communicating with a plant-based community make it easier to swap recipes or locate the best restaurants serving vegan and vegetarian-friendly cuisine.

PlantX Flagship Locations – British Columbia (Canada), San Diego (California), & the State of Israel

PlantX will link the e-commerce platform to flagship brick-and-mortar stores for a highly sensory customer experience. This is anticipated to drive corporate growth and global brand recognition.

These PlantX branded flagship locations will first launch in:

Customer engagement, education and creating a global plant-based community will be furthered through this initiative.

PlantX Restaurant Partnerships

With consumers becoming better informed and more health and environmentally conscious, a growing number of restaurants will start catering to the needs of customers who are vegan, vegetarian, have food-allergies (or specialized diets), or simply want to eat healthier.

PlantX proactively aims to support this change and help restaurants meet the needs of the plant-based community. Restaurants that want to increase revenue, drive traffic and make an impact can therefore partner with PlantX to better serve their customers by expanding and refining their menus.

Future Goals for PlantX Life

Having successfully completed all of the milestones that PlantX had set-out to achieve in the second half of 2020, PlantX strives to continue scaling through organic growth, strategic partnerships and accretive M&A opportunities. The upcoming plans from PlantX includes a global expansion strategy for distribution in North America, Europe and Israel.

Verticals launched in 2020 include:

  • New meals and programs by renowned chefs
  • Flagship PlantX locations
  • PlantX branded goods
  • United States meal delivery and LIV
  • Online peer-to-peer fitness

Management Team

Sean Dollinger, the Founder of PlantX Life Inc., has had a very active professional career that started when he was only 17. While still in college, he started a delivery service that soon became one of Canada’s largest delivery firms (before companies like Postmates and Uber Eats ever existed). In 2014, Mr. Dollinger founded Namaste Technologies, the largest international e-commerce distributor of vaporizers and accessories. He brought Namaste public and turned it into a $1.2 billion business in two years. After finding a plant-based diet himself, and seeing the massive benefits that it provided for him, he decided he wanted to find a way to give back to the community and focus on something he loves. PlantX Life was born from this desire and became his passion project. He truly walks the talk.

Julia Frank is the CEO of PlantX Life. She has an MBA in digital entrepreneurship, and, in her past roles, she set up renowned strategies for large corporations like BMW and Daimler in Germany. Beyond her professional business prowess, Ms. Frank finds tremendous joy in preparing delicious and nutritious plant-based meals and is the face of the company. She practices a healthy and active lifestyle that includes experiencing as many cultures as possible to add more knowledge of the industry at large. This globally inclusive perspective gives her the unique advantage of being able to see plant-based living from all angles.

Lorne Rapkin, CPA, CA, LPA, is the President and CFO of PlantX Life and is also a partner at Rapkin Wein LLP. He has experience with clients in almost every industry, including finance, professional services, real estate, automotive, media and manufacturing. Mr. Rapkin works very closely with investment and public firms, seeking to comply with IFRS accounting standards. His roles often require him to work with management on go-public transactions, acquisitions and mergers. His keen attention to detail is an asset to any client he works with, and PlantX is no exception.

Alex Hoffman is the company’s CMO and has spent the last 10 years in the creative field cultivating her passion for design and appreciation for beauty. This is apparent in all of the creative decisions and outcomes seen at PlantX. Her role within the company is to oversee all of the brand marketing activities, establish and execute key processes for rapid growth, and work closely with management to refine the brand’s message for key segments and emerging opportunities. She has a sharp vision for exactly what’s needed to convey the company’s core messages and principles to both the public and investors, and she is a visionary with respect to creative marketing ideas and concepts.

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), closed Wednesday’s trading session at $1.08, off by 6.087%, on 262,790 volume. The average volume for the last 3 months is 187,290 and the stock's 52-week low/high is $0.349999994/$1.85000002.

Recent News

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF)

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF).

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, has recently updated investors following the successful completion of the second tranche of their non-brokered private placement offering of special warrants (https://cnw.fm/Cfk2b). Following the close of the second tranche, which resulted in Pure Extracts issuing an aggregate 10,839,230 special warrants for gross proceeds of $5,473,811.14, the company will have raised a total of $8,534,632.81 from its private placement. Also today, the company was featured in a publication from PsychedelicNewsWire, examining how PRXTF has announced that it has completed its application for new company registration with the Natural and Non-prescription Health Products Directorate (“NNHPD”) and subsequently has received its company code. As a result, Pure Extracts can now submit an application for a Class 1 Natural Product Number (“NPN”) for a functional mushroom product. PULL anticipates this will be the first of several NPN applications it submits in 2021. 

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF), headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extracts is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.

Pure Extracts Technologies Corp. (PRXTF), closed Wednesday’s trading session at $0.4773, up 0.146874%, on 107,717 volume. The average volume for the last 3 months is 76,811 and the stock's 52-week low/high is $0.438603997/$1.00.

Recent News

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: ISGIF)

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: ISGIF).

InsuraGuest Technologies (TSXV: ISGI) (OTCQB: ISGIF), through its wholly owned U.S. subsidiary InsuraGuest Risk Purchasing Group Inc. ("ISG"), today announced that it has renewed its annual contract with Wintergreen Resort in Wintergreen, Virginia. Under the contract, the company will supply its InsuraGuest Hospitality Liability coverages, which cover claims made by resort guests on a primary basis. According to the update, InsuraGuest's Hospitality Liability coverages and platform protected 23,917 room nights for US$4.95 a night at the 200-room Wintergreen Resort in 2020. To view the full press release, visit https://ibn.fm/JLvRB

InsuraGuest Technologies, Inc. (TSX.V: ISGI) (OTC: ISGIF) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.

InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.

The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.

InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.

Protection that Enhances the Guest’s Experience

InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Investment Consideration

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.

Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.

Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.

Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.

Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.

InsuraGuest Technologies, Inc. (ISGIF), closed Wednesday’s trading session at $0.2074, off by 16.202%, on 7,389 volume. The stock's 52-week low/high is $0.079300001/$0.248799994.

Recent News

Grapefruit USA Inc. (OTCQB: GPFT)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit USA Inc. (OTCQB: GPFT).

Grapefruit USA (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products. The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses. Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Grapefruit USA Inc. (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products.

The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses.

Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace.

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids.

Hourglass™ allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

Hourglass™ provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) in a Patchless Patch™ system that is novel and proprietary to the company.

Hourglass™ Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass™ by Grapefruit.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.

Grapefruit Cannabis Services

Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

  • Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass™ topical delivery cream.
  • Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass™ cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
  • Hourglass™ Topical THC+CBD Delivery Cream – The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
  • Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook

The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://nnw.fm/eTMSX).

Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology.

Management Team

Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility.

Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations.

Grapefruit USA Inc. (OTCQB: GPFT), closed Wednesday’s trading session at $0.0465, off by 4.7619%, on 558,229 volume. The average volume for the last 3 months is 1,056,650 and the stock's 52-week low/high is $0.013624999/$0.103.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Monday's trading